Rebiotix, Inc.

Clostridioides difficile infection (CDI) is a billion-dollar problem that microbiome-targeted companies are keen to solve. CDI is arguably the lowest-hanging fruit for microbiome-focused companies as

Just shy of three years after Ferring Pharmaceuticals and Blackstone formed FerGene to advance the late-stage bladder cancer gene therapy nadofaragene firadenovec, the pharma company and the priva

The waning of the COVID-19 pandemic was reflected in three FDA decisions issued last week for applications that had been under review long past their user fee goal dates because manufacturing inspecti

With understanding of immune function advancing in leaps and bounds and a continuing proliferation of tools to manipulate it, expectations are high for advances in oncology and immunology over the com